|Bid||218.67 x 100|
|Ask||218.75 x 100|
|Day's Range||217.11 - 223.04|
|52 Week Range||184.50 - 256.80|
|PE Ratio (TTM)||6.65|
|Dividend & Yield||2.80 (1.27%)|
|1y Target Est||N/A|
Is Allergan (AGN) a great pick from the value investor's perspective right now? Read on to know more.
Shares of Allergan (AGN) are rising today after J.P. Morgan analyst Chris Schott said the drug maker’s stock could climb more than 30% in the next year. Allergan’s share price has fallen more than 12% since it hit a 52-week high of $256.80 in late July. Overall, we believe several controversies (most notably the timing of generic Restasis competition) have taken focus away from a highly attractive core franchise at Allergan and as we look out to 2018, we see an increasingly compelling setup for AGN shares with both pipeline optionality and a strong SOTP valuation argument.
Patent lawyers are intrigued and competitors will likely challenge, but the move to transfer ownership of the patent to the Saint Regis Mohawk tribe could cause other companies to try a similar tack.